Literature DB >> 9717688

Ehrlichia antibodies, leukopenia and thrombocytopenia in initial phase of tick-borne encephalitis.

S Lotric-Furlan, M Petrovec, T Avsic-Zupanc, F Strle.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9717688     DOI: 10.1007/bf02962378

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  7 in total

Review 1.  Tick-borne diseases in the United States.

Authors:  D H Spach; W C Liles; G L Campbell; R E Quick; D E Anderson; T R Fritsche
Journal:  N Engl J Med       Date:  1993-09-23       Impact factor: 91.245

2.  An indirect immunofluorescence assay using a cell culture-derived antigen for detection of antibodies to the agent of human granulocytic ehrlichiosis.

Authors:  W L Nicholson; J A Comer; J W Sumner; C Gingrich-Baker; R T Coughlin; L A Magnarelli; J G Olson; J E Childs
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

3.  Human disease in Europe caused by a granulocytic Ehrlichia species.

Authors:  M Petrovec; S Lotric Furlan; T A Zupanc; F Strle; P Brouqui; V Roux; J S Dumler
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

4.  Thrombocytopenia, leukopenia and abnormal liver function tests in the initial phase of tick-borne encephalitis.

Authors:  S Lotric-Furlan; F Strle
Journal:  Zentralbl Bakteriol       Date:  1995-04

5.  Thrombocytopenia--a common finding in the initial phase of tick-borne encephalitis.

Authors:  S Lotric-Furlan; F Strle
Journal:  Infection       Date:  1995 Jul-Aug       Impact factor: 3.553

6.  Human granulocytic ehrlichiosis in the upper Midwest United States. A new species emerging?

Authors:  J S Bakken; J S Dumler; S M Chen; M R Eckman; L L Van Etta; D H Walker
Journal:  JAMA       Date:  1994-07-20       Impact factor: 56.272

Review 7.  Ehrlichial diseases of humans: emerging tick-borne infections.

Authors:  J S Dumler; J S Bakken
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.